Plus Therapeutics, Inc.
Plus Therapeutics, Inc. (PSTV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pstv · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$25.00
Consensus
$25.00
+352.1% upside
Low
$25.00
Median: $25 · Last Close: $5.53
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.29 | ↓ 4.30% |
1-day model range: $5.17–$5.42. Peak: $5.42 (-4.30%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · PSTV · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-08 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-04-09 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-03-31 | D. Boral Capital | Downgrade ↓ | Buy→Hold |
| 2026-03-19 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-22 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-11 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-01 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-21 | Ascendiant Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Plus Therapeutics, Inc. (PSTV) stock. Of the recent 37 rating actions, 1 were upgrades and 2 were downgrades. 4 analysts currently cover PSTV.
Analyst Recommendation Trends
PSTV analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$6M
↓ 86.7% YoY
Revenue Next Year
$19M
↑ 217.0% YoY
EPS This Year
$-3.87
EPS Next Year
$-2.37
↓ 38.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast PSTV EPS of $-3.87 for the current fiscal year, based on estimates from 3 analysts. The PSTV revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PSTV stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PSTV price target is $25.00 (+352.1% upside), with an analyst consensus of Buy.
The PSTV short-term stock prediction for tomorrow is $5.29 (-4.30%).
Plus Therapeutics, Inc. trades on NASDAQ under the ticker PSTV. The PSTV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
PSTV forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month PSTV price target is $25.00, with a high forecast of $25.00 and a low of $25.00. The median price target is shown in the chart above when available. This implies +352.1% potential upside from the current price of $5.53.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.